FDA Fellowship - Systematic Evaluation of Factors Affecting Disease , Pharmacodynamics and Treatment

Organization

U.S. Food and Drug Administration (FDA)

FDA-CDER-

11/20/2026 3:00:00 PM Eastern Time Zone

• Applications will be reviewed on a rolling-basis.

A research opportunity is available immediately with the Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), located in Silver Spring, Maryland.

The Center for Drug Evaluation and Research (CDER) performs an essential public health task by making sure that safe and effective drugs are available to improve the health of people in the United States. As part of the U.S. Food and Drug Administration (FDA), CDER regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs. These efforts cover more than just medicines.

During this appointment, you will have the opportunity to participate in the systematic evaluation of factors affecting disease progression, pharmacodynamics and treatment response in neurodegenerative conditions such as Parkinson's disease. This data-driven research will utilize clinical trial data submitted to the agency as part of NDA/BLA submissions. You will have access to unique research and training opportunities, ability to interact with top regulatory scientists and use state-of-the‑art techniques.

• Learn about various neurodegenerative diseases (e.g., Parkinson’s disease) including the pathophysiology, pharmacokinetics/pharmacodynamics of available treatment options, clinical trial designs, and drug development approaches.
• Gain expertise in data collection & handling, database building, and various contemporary data exploration/analyses techniques.
• Learn and contribute to data-driven dynamic disease-progression modeling for neurodegenerative diseases.

The mentor for this opportunity is Sreedharan Sabarinath (sreedharan.sabarinath.gov). If you have questions about the nature of the research, please contact the mentor.

October 2026. Start date is flexible and will depend on a variety of factors.

The appointment will initially be for one year, but may be renewed upon recommendation of FDA and is contingent on the availability of funds.

The appointment is full time.

The participant will receive a monthly stipend commensurate with educational level and experience.

This opportunity is available to U.S. citizens, Lawful Permanent Residents (LPR), and foreign nationals. Non-U.S. citizen applicants should refer to the Guidelines for Non-U.S. Citizens Details page of the program website for information about the valid immigration statuses that are acceptable for program participation.

This program, administered by ORAU through its contract with the U.S. Department of Energy to manage the Oak Ridge Institute for Science and Education, was established through an interagency agreement between DOE and FDA. The participant will receive a monthly stipend commensurate with educational level and experience. Proof of health insurance is required for participation in this program. Participants do not become employees of FDA, DOE or the program administrator, and there are no employment-related benefits.

Completion of a successful background investigation by the Office of Personnel Management is required for an applicant to be on-boarded  can complete a background investigation only for individuals, including non-US Citizens, who have resided in the US for a total of three of the past five years.

If an ORISE Fellow, to include their spouse and minor children, reports what is identified as a…